Martín-Núñez Javier, Heredia-Ciuró Alejandro, López-López Laura, Calvache-Mateo Andrés, Hernández-Hernández Sofía, Valenza-Peña Geraldine, Valenza Marie Carmen
Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Av. De la Ilustración, 6018016 Granada, Spain.
Healthcare (Basel). 2023 Nov 8;11(22):2925. doi: 10.3390/healthcare11222925.
Idiopathic pulmonary fibrosis (IPF) is one of the most deleterious diseases of the pulmonary fibrosis spectrum. Its clinical presentation includes irreversible loss of lung function, and increasing cough, dyspnea and impaired quality of life. Chest physiotherapy can improve ventilation capacity, gas exchange, dyspnea, exercise capacity and quality of life. The aim of this study was to review the evidence about chest physiotherapy in IPF, specifically meta-analyzing quality of life, exercise capacity and pulmonary function.
A wide search was conducted in PubMed, Embase, Cochrane and Web of Science for articles included until October 2023. PROSPERO Identifier: CRD42022333496. The Downs and Black scale and the Cochrane tool were employed to evaluate quality assessments and to assess the risk of bias. Data were pooled, and a meta-analysis was conducted.
We selected 10 studies in which a chest physiotherapy program was performed with a total of 340 patients; of these, three articles were meta-analyzed. Significant effects in favor of chest physiotherapy were found for quality of life (MD = -8.60, 95% CI = -11.30, -5.90; < 0.00001; I = 24%), exercise capacity (MD = 37.62, 95% CI = 15.10, 60.13; = 0.001; I = 65%) and pulmonary function (MD = 7.86, 95% CI = 2.54, 13.17; = 0.004; I = 80%).
The systematic review showed significant results for the application of chest physiotherapy regarding pulmonary capacity, diffusion of gases and quality of life in IPF patients. The meta-analysis showed a significant improvement associated with applying chest physiotherapy in pulmonary function, exercise capacity and quality of life.
特发性肺纤维化（IPF）是肺纤维化谱系中最具危害性的疾病之一。其临床表现包括肺功能不可逆转的丧失，以及咳嗽、呼吸困难加重和生活质量受损。胸部物理治疗可改善通气能力、气体交换、呼吸困难、运动能力和生活质量。本研究的目的是回顾有关IPF胸部物理治疗的证据，特别是对生活质量、运动能力和肺功能进行荟萃分析。
在PubMed、Embase、Cochrane和Web of Science中广泛检索截至2023年10月的文章。PROSPERO标识符：CRD42022333496。采用唐斯和布莱克量表以及Cochrane工具进行质量评估和偏倚风险评估。汇总数据并进行荟萃分析。
我们选择了10项进行胸部物理治疗方案的研究，共340例患者；其中3篇文章进行了荟萃分析。在生活质量（MD = -8.60，95%CI = -11.30，-5.90；P < 0.00001；I² = 24%）、运动能力（MD = 37.62，95%CI = 15.10，60.13；P = 0.001；I² = 65%）和肺功能（MD = 7.86，95%CI = 2.54，13.17；P = 0.004；I² = 80%）方面发现了有利于胸部物理治疗的显著效果。
系统评价显示，胸部物理治疗在IPF患者的肺容量、气体扩散和生活质量方面的应用取得了显著结果。荟萃分析表明，应用胸部物理治疗在肺功能、运动能力和生活质量方面有显著改善。
